Substance / Medication

Tarlatamab

Overview

Active Ingredient
tarlatamab
RxNorm CUI
2682954

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
Mountzios Giannis, Sun Longhua, Cho Byoung Chul et al. · N Engl J Med · 2025
PMID: 40454646RCT
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Zhang Bingnan, Alder Laura, Rosner Samuel et al. · Lung Cancer · 2026
PMID: 41371100Observational
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From-Rearranged NSCLC: Case Report.
Wang Kaiwen, Taslic Ceylan Altintas, de Groot Patricia et al. · JTO Clin Res Rep · 2026
PMID: 41584719Case ReportFull text (PMC)
Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report.
Zhang Bingnan, Shah Komal B, Parma Mitchell et al. · J Thorac Oncol · 2025
PMID: 40126456Case ReportFull text (PMC)
Tarlatamab-Induced Tumor Lysis Syndrome in Small Cell Carcinoma: Case Series.
Lobsiger Brook M, Huh-Brown Ashley S, Edmisson Jacob S et al. · Clin Lung Cancer · 2025
PMID: 41109815Case Report
Rapid disease progression and hydrocephalus following tarlatamab therapy initiation: A case report.
Fukui Doppo, Sakakibara-Konishi Jun, Azuma Riku et al. · Respir Med Case Rep · 2025
PMID: 41311375Case ReportFull text (PMC)
Tarlatamab Rechallenge After Grade 3 Cytokine Release Syndrome Leading to Tumor Regression in Two Weeks and Reopening of a Collapsed Lung: A Case Report.
Schieber Timothy, Neupane Prakash, Li Haoran et al. · Clin Lung Cancer · 2025
PMID: 39757042Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Tarlatamab (substance)
SNOMED CT
92911000087102
UMLS CUI
C5446797
RxNorm CUI
2682954

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.